Using AI to Study and Improve Diagnosis and Treatment of Parkinsons, Alzheimers, and Other Neurological and Geriatric Diseases

What this Trial Is About

Researchers are studying the characteristics of handwriting, gait, speech, eye movements, and biological samples in patients with Alzheimers disease, Parkinsons disease, other neurological disorders, and elderly individuals. The study aims to evaluate these features alongside imaging and EEG markers using AI technology to improve diagnosis and treatment for geriatric diseases. The research includes 100 patients with Parkinsons, 100 with Alzheimers, 100 with other neurological disorders, 80 healthy elderly controls, and 80 healthy young controls. Participants undergo assessments such as motor function tests for Parkinsons patients and cognitive and mood evaluations for Alzheimers patients. All subjects complete handwriting recording, gait assessment, language and eye movement recordings, and provide biological samples including blood, urine, stool, and saliva. Imaging and EEG data are also collected to analyze correlations with clinical features using AI. Data is carefully collected, entered, and analyzed by clinical and statistical experts. During the study, participants provide multiple types of data at regular intervals from early 2022 through mid-2026. Evaluations include cognitive scales like the MMSE and MOCA, motor assessments like UPDRS, and mood scales such as HAMD. The research team monitors markers from handwriting to EEG over time to better understand these diseases. The study involves ongoing data collection and statistical analysis to identify meaningful patterns that could aid diagnosis and treatment planning.

Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases